-transparent.png){kind=logo}
The objective of this investigation was to study the effects of maytansine on the cell cycle kinetics of HeLa cells. The results of this study indicate that maytansine is a very potent mitotic inhibitor and that it has no effect on macromolecular synthesis. Maytansine-induced cytotoxicity was dependent upon the position of the cell in the cell cycle. Mitotic and G2 cells are most sensitive to this agent, while G1 phase cells are the most resistant, with S-phase cells being intermediate. Small (0.82 X 10(-8) M) fractionated doses given at an interval of 8 hr have been found to be more cytotoxic than was a large (1.63 X 10(-8) M) single dose. In evaluating the drug combinations, we observed that the schedule in which 1-beta-D-arabinofuranosylcytosine treatment was followed by maytansine treatment exhibited greater cell kill than the reverse sequence. No schedule-dependent effects were observed when maytansine was tried in combination with Adriamycin.
P N Rao, and
E J Freireich, and
M L Smith, and
T L Loo
October 1975,
Bibliotheca haematologica,
P N Rao, and
E J Freireich, and
M L Smith, and
T L Loo
February 1972,
Cancer research,
P N Rao, and
E J Freireich, and
M L Smith, and
T L Loo
March 1978,
Cancer treatment reports,
P N Rao, and
E J Freireich, and
M L Smith, and
T L Loo
July 1988,
Journal of the National Cancer Institute,
P N Rao, and
E J Freireich, and
M L Smith, and
T L Loo
January 1988,
Cancer chemotherapy and pharmacology,
P N Rao, and
E J Freireich, and
M L Smith, and
T L Loo
December 1958,
Annals of the New York Academy of Sciences,
P N Rao, and
E J Freireich, and
M L Smith, and
T L Loo
January 2001,
Bioorganic & medicinal chemistry letters,
P N Rao, and
E J Freireich, and
M L Smith, and
T L Loo
September 1999,
Journal of medicinal chemistry,
P N Rao, and
E J Freireich, and
M L Smith, and
T L Loo
November 1980,
Research communications in chemical pathology and pharmacology,
P N Rao, and
E J Freireich, and
M L Smith, and
T L Loo
April 2007,
Cancer research,
